Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17201112 | 0.88 | UCHL1 (0.34) | UCHL1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL17201213 | 0.84 | UCHL1 (0.33) | UCHL1ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL17201242 | 0.83 | SOS1 (0.36) | UCHL1MAPTPDK2PDK4 | |
| SCHEMBL31727972 | 0.81 | UCHL1 (0.38) | UCHL1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL22367848 | 0.80 | MEN1 (0.35) | UCHL1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL18107886 | 0.80 | CA12 (0.37) | UCHL1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL17201256 | 0.80 | ALDH1A1 (0.40) | UCHL1KMT2AALDH1A1HPGDCYP3A4 | |
| SCHEMBL20477784 | 0.78 | KDM4E (0.39) | UCHL1ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL20636640 | 0.78 | UCHL1 (0.34) | UCHL1ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL20636622 | 0.78 | KDM4E (0.37) | UCHL1KMT2AALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-15 | — | — | US | disclosed |
| EP-3134386-B1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-20 | — | — | EP | disclosed |
| US-10457670-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190241547-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20180346452-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-06 | — | — | US | disclosed |
| US-9868725-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| EP-3134386-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | Takeda Pharmaceutical Company Limited (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044143-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170027921-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-02 | — | — | US | disclosed |
| US-9518042-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-13 | — | — | US | disclosed |
| US-9499516-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9315458-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| WO-2015163485-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | UCHL1 1218/4885MEN1 2085/4885KMT2A 1067/4885 |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
| US-20180346452-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | CHRM1, CHRM2, CHRM5 | UCHL1 676/4885MEN1 2760/4885KMT2A 817/4885 |
| US-20170027921-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRNA5 | UCHL1 1165/4885MEN1 3085/4885KMT2A 528/4885 |
| US-20190241547-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
| US-20170044143-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | CHRM1, CHRM2, CHRM5 | UCHL1 729/4885MEN1 2794/4885KMT2A 871/4885 |
| US-10457670-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | CHRM1, CHRM2, CHRM5 | UCHL1 676/4885MEN1 2760/4885KMT2A 817/4885 |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | UCHL1 1417/4885MEN1 1599/4885KMT2A 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.